Astrazeneca takes $100m hit on failed heart disease drug tests January 13, 2020 Astrazeneca is in line for a $100m hit after a heart disease drug was shown to be ineffective in treating certain heart conditions in tests. After the disappointing results, the drug manufacturer said it would stop running trials on the drug, known as Epanova. Read more: Astrazeneca beats estimates in strong third quarter It also [...]
Astrazeneca pushes further into China with trio of new projects November 6, 2019 Astrazeneca this morning unveiled three new initiatives to further deepen the UK-based company’s footprint in China. The pharmaceuticals multinational has agreed a partnership with China International Capital Corporation (CICC), one of China’s leading investment banks, to create a $1bn Healthcare Industrial Fund. Read more: AstraZeneca beats estimates in strong third quarter Astrazeneca will be a [...]
Astrazeneca share price hits record high on ‘exceptionally impressive’ trial results September 2, 2019 Shares in Astrazeneca reached a record high today after the company kicked off September with strong results from two drug trials. The company’s share price ticked up as much as 3.6 per cent to 7,583p, as it said drug Brilinta, when taken with aspirin, lowered the risk of heart attacks and strokes in several types [...]
Astrazeneca makes lupus breakthrough August 29, 2019 Astrazeneca today took a leap forward for lupus patients who have been waiting for decades for a breakthrough, bouncing back from disappointing results last year. The second round of phase three trials for anifrolumab, a new drug, showed positive results on lupus patients, the company said this morning. Read more: Astrazeneca gets boost as good [...]
Astrazeneca gets boost as good news comes in pairs August 28, 2019 Astrazeneca got a double immune boost today as one of its drugs was given orphan status in the US, while trials of a pulmonary medicine showed positive results. The firm said its medicine Fasenra was granted special status as an orphan drug in the US. Orphans are medicines that treat rare diseases. Read more: Astrazeneca [...]
Astrazeneca faces setback in lung cancer trials August 21, 2019 Astrazeneca took a blow this morning as it revealed that trials of a lung cancer drug had not lived up to hopes pinned on it. Patients given Imfinzi with tremelimumab did not show better overall survival rates than those on standard chemotherapy, Astra said this morning. Read more: Heart patients given boost by Astrazeneca drug [...]
Heart patients given boost by Astrazeneca drug trials August 20, 2019 A new Astrazeneca drug might help patients with heart failure, half of whom die within five years of being diagnosed, as the company this morning showed encouraging trial results. The Anglo-Swedish drugmaker said that the third phase of trials of its Farxiga medicine significantly reduced cardiovascular death or prevented heart failure from getting worse. Read [...]
Astrazeneca share price rises as new cancer drugs boost sales July 25, 2019 Shares in Astrazeneca rose more than five per cent this morning after bumper sales of new cancer drugs fuelled a revenue rise in the second quarter. Read more: Astrazeneca promises cash to back up £12m redundancy payments for former staff The FTSE 100 pharmaceutical giant posted a 14 per cent rise in sales to $5.7bn [...]
GSK eyes former Astrazeneca CFO for empty chair July 14, 2019 Drugmaker Glaxosmithkline is set to announce the former finance boss of Astrazeneca as its new chair to oversee the breakup of the business. GSK is preparing to appoint Jonathan Symonds as its new non-executive chair, Sky News reported earlier. Read more: GSK to split as it forms £9.8bn consumer health venture with Pfizer The announcement [...]
Our healthcare system is trapped in an impasse as pharmaceutical firms struggle to fund medical innovations May 1, 2019 The price of technological innovations in health care has once again been brought into focus. Orkambi, a new pharmaceutical treatment for a specific type of cystic fibrosis has not been approved for availability on the NHS because its price is deemed too high. Meanwhile, there is panic at the relentless rise of fatal antibiotic-resistant infections [...]